Printer Friendly

Positron PET Device Approved in Canada.

HOUSTON -- Positron Corporation (OTCBB:POSC) today announced that the Company has recently received approval from Health Canada to use Positron's mPower PET scanner in oncology and cardiology clinical trials in Canada. Positron is developing a broad range of applications and upgrades to its mPower line and will be rapidly expanding the approved uses of its mPower product in Canada.

Positron is well positioned to take advantage of Health Canada's approval of Positron's PET device by offering its mPower product to Canadian health care providers as a more cost-effective solution to the more traditionally expensive PET and PET/CT products currently available in the marketplace. Positron will comply with Health Canada to provide cost effective studies to support wide spread dissemination across all provinces.

Positron President, Joe Oliverio states: "This represents a continuation of our business strategy in Positron to be a global PET provider that will deliver an affordable medical device with superior software solutions catered to markets that possess limited healthcare resource dollars although demand excellent quality medical care. We believed for a long time that the Canadian market would be ideal for widespread use of PET scanning since many studies have shown to reduce overall healthcare expenditures to the government payers while improving patient outcomes."

About Positron

Positron Corporation designs, manufactures, markets and supports advanced medical imaging devices utilizing positron emission tomography (PET) technology under the trade name POSICAM(TM) systems. POSICAM(TM) systems incorporate patented and proprietary software and technology for the diagnosis and treatment of patients in the areas of cardiology, oncology and neurology. Positron Corporation offers unique combination of low cost technology and disease specific software solutions differentiating themselves from all other medical device manufacturers. POSICAM(TM) systems are in use at leading medical facilities, including the University of Texas -- Houston Health Science Center; The Heart Center of Niagara in Niagara Falls, New York; Beth Israel, New York; Emory Crawford Long Hospital Carlyle Fraser Heart Center in Atlanta; and Nishidai Clinic (Diagnostic Imaging Center) in Tokyo. Additional information may be found at

Forward Looking Statements

Certain statements in this release, and other written or oral statements made by the Company, including the use of the words "expect," "anticipate," "estimate," "project," "forecast," "outlook," "target," "objective," "plan," "goal," "pursue," "on track," and similar expressions, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied. The Company assumes no obligation and does not intend to update these forward looking statements. Among the important factors that could cause actual results to differ materially from those indicated by such forward looking statements include, without limitation: competitive and general economic conditions, adverse effects of litigation, the timely development and acceptance of services, significant changes in the competitive environment, the failure to generate or the loss of significant numbers of customers, the loss of senior management, increased government regulation or the company's failure to integrate its acquired companies to achieve the synergies and efficiencies described in the "Management's Discussion and Analysis" section of the Company's Form 10-KSB and other reports and filings with the Securities and Exchange Commission, which may be revised or supplemented in subsequent reports on SEC Forms 10-QSB and 8-K.

For further information please contact Positron Corporation at (281) 492-7100.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Mar 22, 2006
Previous Article:Bike Trails of Wisconsin's Chippewa Valley Expect Continued Visitor Spike in 2006; Extended Trail System, Family Activities and Abundant Wildlife...
Next Article:Ubisoft Supports AGEIA PhysX Processor in ''Tom Clancy's Ghost Recon Advanced Warfighter(TM)''; AGEIA Solutions Partner Creates Physics-Based...

Related Articles
Mediastinal staging of non-small cell lung carcinoma using computed and positron-emission tomography.
Positron Corporation Officially Opens Joint Venture with Neusoft Medical Systems of China.
Imagin Molecular Corporation Enters into Coronary Artery Disease Reversal and Prevention Centers Market.
Quantitative Software System Sets Positron as the Leader in Diagnostic and Management Needs for Coronary Artery Disease.
Positron Acquires IS2 Medical Systems, a Nuclear Imaging Device Manufacturer.
Positron Corporation Funds Research for Niagara University's Academic Center For Integrated Sciences.
Positron Corporation's Affiliate Imaging PET Technologies Records Its 150th Sale of Its IS2 SPECT Camera.
Positron Corporation to Provide MIMcardiac(TM) Software with mPower(TM) PET Scanners.
Positron Corporation Research Coverage Initiated by Beacon Equity Research.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters